Abstracts S45 Disclosure statement: Dr. Wajs is an employee of Janssen Research & Development and holds company stock doi: 10.1016/j.euroneuro.2018.11.1016 P.013 Vortioxetine versus venlafaxine for major de- pressive disorder: A meta-analysis and systematic re- view B. Maneeton 1,* , N. Maneeton 1 , P. Woottiluk 2 , A. Oonarom 1 , P. Wiriyacosol 1 1 Chiang Mai University, Department of Psychiatry- Faculty of Medicine, Chiang Mai, Thailand 2 Chiang Mai University, Psychiatric Nursing Division- Fac- ulty of Nursing, Chiang Mai, Thailand Background: Although some evidences have shown the comparable efficacy between vortioxetine and venlafaxine in the treatment of major depressive disorder (MDD) [1], a meta-analysis, a more powerful method for determining the true effect size, is a possible better method to examine the efficacy, acceptability and tolerability between such antide- pressants in the treatment of MDD. Objectives: This study aimed to systematically review the efficacy, acceptability and tolerability between vortiox- etine and venlafaxine in treatment of MDD. Data sources: The important databases, including Sco- pus, PubMed, CINAHL and Cochrane Controlled Trials Regis- ter were searched in March 2018. All randomized controlled trial (RCTs) of vortioxetine compared with venlafaxine in the treatment of MDD was eligible in this review. Study appraisal and synthesis methods: The titles and abstracts gathered from electronic search of those databases were detected for the relevant studies. Then, the full-text versions of such relevant trials were collected and, thoroughly examined and extracted. The primary ef- ficacious outcome was the pooled mean-changed scores of the Montgomery– ˚ Asberg Depression Rating Scale (MADRS). However, the pooled mean-changed score of the Clinical Global Impression of Severity (CGI-S), the Clinical Global Im- pression of improvement (CGI-I) and the Hamilton Anxiety Rating Scale (HAM-A), response and remission rate, over- all discontinuation rate and discontinuation rate due to ad- verse events were also calculated. All relative risks (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated by using a random effect model. Results: A total of 650 all-patients treated set (APTS), comprising all randomized patients who took at least one dose of study medication, of two RCTs were included in this study [2,3]. The MARDS, CGI-S and CGI-I rating scales were applied to evaluated severity of depressive symptoms in both included studies. The pooled mean-changed scores of the MARDS, CGI-S and CGI-I between two treated groups had no significant difference with WMD (95% CI) of -0.53 (- 2.32, 1.26), I2=18%, -0.09(-0.29, 0.12), I2=0% and -0.07(- 0.28, 0.14), I2=18%, respectively. Similarly, the pooled re- sponse and remission rates in two treated groups were not significantly different with RRs (95% CI) of 0.95(0.73, 1.24), I2=26% and 1.01(0.88, 1.16), I2=0%, respectively. Ad- ditionally, the pooled mean-changed scores of the HAMA between two treated groups had also no significant dif- ference with WMD (95% CI) of -0.62(-1.73, 0.49), I2=0%. The pooled overall discontinuation rate was not different between the two groups with RR (95% CI) of 0.77(0.51, 1.16), I2=37%. Unfortunately, the discontinuation rate due to adverse events in venlafaxine-treated group was higher than that of vortioxetine-treated group with RR (95% CI) of 0.48(0.29, 0.78), I2=0%. Conclusions: Efficacy of vortioxetine and venlafaxine in the treatment of MDD is comparable. Additionally, their ef- ficacy in the treatment of anxiety in such patients is also comparable. The acceptability in both active agents is com- parable. However, the tolerability of venlafaxine is less than vortioxetine. Since small studies included in this review, application of present evidences should be careful in the clinical practice. Hence, the further well-defined and large sample-size studies should be conducted to determine these outcomes. Disclosure statement: Benchalak Maneeton received hono- raria and/or travel reimbursement from Lundbeck, Pfizer and Servier. Narong Maneeton received travel reimburse- ment from Lundbeck and Pfizer. Pakapan Woottiluk, Awirut Oonarom, Punjaree Wiriyacosol had no potential conflicts of interest. References [1] Citrome, L., 2016. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levom- ilnacipran, sertraline, venlafaxine, and vilazodone, using num- ber needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 196, 225–233. [2] Alvarez, E., Perez, V., Dragheim, M., Loft, H., Artigas, F., 2012. A double-blind, randomized, placebo-controlled, active refer- ence study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15, 589–600. [3] Wang, G., Gislum, M., Filippov, G., Montgomery, S., 2015. Com- parison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin 31, 785–794. doi: 10.1016/j.euroneuro.2018.11.1017 P.014 Biological changes in a pharmacologically– induced depression model confirm the role of estro- gen sensitivity in perinatal depression D. Mehta 1 , M. Rex-Haffner 2 , H.B. Søndergaard 3 , A. Pinborg 4 , E. Binder 2 , V.G. Frokjaer 5,* 1 Queensland University of Technology- School of Psychology and Counselling- Faculty of Health, Institute of Health and Biomedical Innovation-, Kelvin Grove, Australia 2 Dept. of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany 3 Danish Multiple Sclerosis Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark 4 Fertility Clinic, Copenhagen University Hospital Rigshos- pitalet, Copenhagen, Denmark